Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Annales Medico-Psychologiques
|
June 1, 1984
[Factorial structure of the A.M.D.P.: comparison with German language studies and originality of the French adaptation]
B Troisfontaines, D Bobon, C Digonnet, et al.
Life Sciences
|
January 1, 1994
Characterization of somatostatin receptors and growth inhibition by the somatostatin analogue BIM23014 in small cell lung carcinoma xenograft: SCLC-6
G Prévost, Y Bourgeois, C Mormont, et al.
Acta Psychiatrica Belgica
|
March 1, 1987
[A problem detected by the AMDP rating of the Mar. case: the relation between phobia and obsession]
J Pellet, C Mormont, F Lang, et al.
Chronobiology International
|
May 1, 1996
The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients
D Minors, T Akerstedt, G Atkinson, et al.
Psychoneuroendocrinology
|
January 1, 1987
Intranasal oxytocin in obsessive-compulsive disorder
M Ansseau, J J Legros, C Mormont, et al.
Investigational New Drugs
|
December 1, 1988
Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin
M C Mormont, R von Roemeling, R B Sothern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2000
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status
M C Mormont, J Waterhouse, P Bleuzen, et al.
Acta Psychiatrica Belgica
|
July 1, 1982
[Factor analysis of the French revision of the AMDP rating scales. Results of an international study of 388 cases]
D Bobon, C Mormont, A Doumont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A R Abdul Razak, D Soulières, S A Laurie, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Annales Medico-Psychologiques
|
June 1, 1984
[Factorial structure of the A.M.D.P.: comparison with German language studies and originality of the French adaptation]
B Troisfontaines, D Bobon, C Digonnet, et al.
Life Sciences
|
January 1, 1994
Characterization of somatostatin receptors and growth inhibition by the somatostatin analogue BIM23014 in small cell lung carcinoma xenograft: SCLC-6
G Prévost, Y Bourgeois, C Mormont, et al.
Acta Psychiatrica Belgica
|
March 1, 1987
[A problem detected by the AMDP rating of the Mar. case: the relation between phobia and obsession]
J Pellet, C Mormont, F Lang, et al.
Chronobiology International
|
May 1, 1996
The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients
D Minors, T Akerstedt, G Atkinson, et al.
Psychoneuroendocrinology
|
January 1, 1987
Intranasal oxytocin in obsessive-compulsive disorder
M Ansseau, J J Legros, C Mormont, et al.
Investigational New Drugs
|
December 1, 1988
Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin
M C Mormont, R von Roemeling, R B Sothern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2000
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status
M C Mormont, J Waterhouse, P Bleuzen, et al.
Acta Psychiatrica Belgica
|
July 1, 1982
[Factor analysis of the French revision of the AMDP rating scales. Results of an international study of 388 cases]
D Bobon, C Mormont, A Doumont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2012
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
A R Abdul Razak, D Soulières, S A Laurie, et al.
Page
of 7